Protara Therapeutics

We're #hiring a new Medical Science Liaison in United States. Apply today or share this post with your network.

May is National #LymphaticMalformations Awareness Month. Lymphatic malformations, or #LMs, are rare, congenital malformations of lymphatic vessels resulting in the failure of these structures to connect or drain into the venous system.   These malformations can lead to serious complications, including recurrent infections, difficulty breathing or swallowing and functional or cosmetic challenges that impact the quality of life.   Despite this burden, there are currently no FDA approved therapies to treat LMs.   Protara stands with patients, families and advocates working to bring greater visibility to LMs and to drive progress toward new treatment options.   Learn more about TARA-002, an investigational therapy being studied for the potential treatment of macrocystic and mixed cystic LMs in pediatric patients: https://lnkd.in/eDseqy8H   #RareDisease

The Protara team was excited to attend #AUA26, hosting a booth and presenting positive updated 12-month data from the BCG-Naïve cohort of the ongoing Phase 2 open-label ADVANCED-2 trial of TARA-002 in patients with carcinoma in situ or CIS (± Ta/T1) Non-Muscle Invasive Bladder Cancer (#NMIBC). Thank you to everyone who engaged in conversation with us in Washington, D.C., and thank you to the American Urological Association for bringing the #BladderCancer research community together in this important forum. Learn more about our presentation: https://lnkd.in/edjN68nw   #Urology #Oncology #ClinicalTrials

Today, we announced positive updated 12-month data from the BCG-Naïve cohort of the ongoing Phase 2 open-label ADVANCED-2 trial of TARA-002 in patients with carcinoma in situ or CIS (± Ta/T1) Non-Muscle Invasive Bladder Cancer (#NMIBC) patients at the American Urological Association Annual Meeting. Learn more: https://lnkd.in/edjN68nw #NMIBC #BladderCancer #Urology #Oncology #AUA26 #ClinicalTrials

Today, Protara announced first quarter 2026 financial results and provided a business update. Read the press release here: https://lnkd.in/e8n6zpXq #NMIBC #ClinicalTrials #Biotech #Urology #Oncology #LifeSciences #BladderCancer #RareDisease #ClinicalNutrition #TARA

We're #hiring a new Executive Director/Vice President of Market Access – Trade, GPOs and Patient Services in New York, New York. Apply today or share this post with your network.

We are excited to spotlight Chris Straub, Business Development Associate at Protara. Chris supports Protara’s corporate strategy by conducting market research, competitive analysis, and assisting in the development and advancement of internal assets. The BD team at Protara collaborates with Research & Development to evaluate the scientific and commercial potential of our pipeline, prepare asset analyses, and identify value drivers. Outside of work, Chris is an avid competitive sailor and is part of a pro-am team that races around the northeast. He enjoys skiing and running regularly, and also loves exploring New York City and reading. Thank you, Chris, for all that you do in support of Protara’s mission to advance transformative therapies for people with cancer and rare diseases. Learn about careers at Protara: https://lnkd.in/dGfNW4m #Hiring #Biotech #LifeSciences #Biotechnology #Leadership

Every successful team knows they can’t achieve their goals without the support of the dedicated administrative professionals who keep everything moving forward. This #AdministrativeProfessionalsDay, we’re celebrating Natalie Halili, Bridget Geoghegan, and Jaymie Berger, Protara’s outstanding administrative professionals! We’re fortunate and proud to have them on our team and appreciate the thoughtfulness, precision and care they bring to their work every day. Natalie, Bridget and Jaymie - thank you for everything you do to support our team and Protara’s mission to advance transformative therapies for people with cancer and rare diseases. Learn about careers at Protara: https://lnkd.in/dGfNW4m #Leadership #Hiring #AdministrativeProfessionals #EmployeeAppreciation

Have you seen our new THRIVE-3 clinical study website? Our THRIVE-3 Phase 2b/3 study is designed to assess the efficacy and safety of low and high dose intravenous #Choline Chloride in adolescent and adult patients receiving long-term parenteral nutrition (PN). We are actively recruiting for this study and are pleased to launch this website with study information and patient resources. Learn more: www.thrive3study.com #RareDisease #Choline #ClinicalNutrition #ParenteralSupport #CholineDeficiency #ClinicalTrials

We're #hiring a new Director, Global Regulatory Affairs in New York. Apply today or share this post with your network.